Clinical Trials Actively Recruiting Patients With Metastatic Breast Cancer


Get Permission

The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on metastatic breast cancer. These studies are researching imaging of metastases; combination chemotherapies; chemotherapy in pretreated disease; and taxane treatment. All of the studies are listed on the National Institutes of Health website at ClinicalTrials.gov.

Pilot

Study Title: Pilot Study of 18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole-Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain

Study Type: Pilot/interventional/parallel assignment

Study Sponsor and Collaborators: Memorial Sloan Kettering Cancer Center

Purpose: To compare two different imaging methods—positron-emission tomography (PET) scanner and magnetic resonance imaging (MRI)—to examine the response of brain metastases from breast cancer to whole-brain radiation therapy

Primary Outcome Measures: Radiographic response [time frame: 1 year]

Principal Investigator: Andrew Seidman, MD, Memorial Sloan Kettering Cancer Center; (646) 888-5445

ClinicalTrials.gov Identifier: NCT01621906

Phase I

Study Title: Phase I Study of Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2-Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System Metastases

Study Type: Phase I/interventional/single-group assignment

Study Sponsor and Collaborators: Memorial Sloan Kettering Cancer Center, Queens Cancer Center of Queens Hospital, University of Michigan

Purpose: To determine if capecitabine can be taken safely with different doses of lapatinib in patients with HER2-positive breast cancer involving brain metastases and/or in spinal fluid (leptomeningeal disease)

Primary Outcome Measures: Maximum tolerated dose [time frame: first 28-day cycle]

Principal Investigator: Andrew ­Seidman, MD, Memorial Sloan Kettering Cancer Center; (646) 888-5445

ClinicalTrials.gov Identifier: NCT02650752

Phase II

Study Title: Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Hormone Receptor–Positive Metastatic Breast Cancer Previously Exposed to Inhibitors of the PI3K Pathway: A Phase II Study With Pharmacodynamic Markers

Study Type: Phase II/interventional/parallel assignment

Study Sponsor and Collaborators: University of California, San Francisco

Purpose: To determine whether palbociclib is more effective combined with fulvestrant or tamoxifen as treatment for metastatic breast cancer

Primary Outcome Measures: Tumor progression as measured by ­RECIST 1.1 [time frame: 16 weeks]

Principal Investigator: Hope S. Rugo, MD, University of California, San Francisco; (415) 353-7618;
hope.rugo@ucsf.edu

ClinicalTrials.gov Identifier: NCT02384239

***

Study Title: Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer

Study Type: Phase II/interventional/single-group assignment

Study Sponsor and Collaborators: University of Washington, National Cancer Institute

Purpose: To study how well eribulin mesylate works in treating patients with previously treated metastatic breast cancer.

Primary Outcome Measures: Progression-free survival [time frame: from study enrollment until the earliest date of disease progression or death, assessed up to 1 year]

Principal Investigator: Hannah Linden, MD, FACP, Fred Hutch/University of Washington Cancer Consortium; multiple locations, go to clinicaltrials.gov for contact ­information.

ClinicalTrials.gov Identifier: NCT01908101

***

Study Title: Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer Patients Who Have Failed an Anthracycline

Study Type: Phase II/interventional/parallel assignment

Study Sponsor and Collaborators: Houston Methodist Research Institute

Purpose: To study the response of breast cancer cells when treated with chloroquine used in combination with chemotherapy. The chemotherapy used in this study is either taxane (paclitaxel) or taxane-like drugs (Abraxane, ixabepilone, or docetaxel).

Primary Outcome Measures: Overall response rate [time frame: 1 year]

Principal Investigator: Jenny C. Chang, MD, The Methodist Hospital System; contact Cancer Center Research, (713) 441-0629; ccresearch@tmhs.org

ClinicalTrials.gov Identifier: NCT01446016

Phase III

Study Title: A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast ­Cancer

Study Type: Phase III/interventional/parallel assignment

Study Sponsor and Collaborators: Academic and Community Cancer Research United

Purpose: To test for the superiority of eribulin mesylate over standard weekly paclitaxel in first- and second-line HER2-negative patients with locally recurrent or metastatic breast cancer.

Primary Outcome Measures: Overall survival of subjects from baseline taking eribulin mesylate vs subjects taking paclitaxel [time frame: baseline until death or up to 4 years]

Principal Investigator: Liu C. Minetta, MD, Academic and Community Cancer Research United; contact Clinical Trials Referrals Office, (855) 776-0015

ClinicalTrials.gov Identifier: NCT02037529 ■

Editor’s Note: The clinical trials presented here do not represent all the trials listed on ClinicalTrials.gov. For the complete list, go to ClinicalTrials.gov.


Advertisement

Advertisement



Advertisement